Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21367
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPapaluca, Timothy-
dc.contributor.authorSinclair, Marie-
dc.contributor.authorGow, Paul J-
dc.contributor.authorPianko, Stephen-
dc.contributor.authorSievert, William-
dc.contributor.authorArachchi, Niranjan-
dc.contributor.authorCameron, Karla-
dc.contributor.authorBowden, Scott-
dc.contributor.authorO'Keefe, Jacinta-
dc.contributor.authorDoyle, Joseph-
dc.contributor.authorStoove, Mark-
dc.contributor.authorHellard, Margaret-
dc.contributor.authorIser, David-
dc.contributor.authorThompson, Alexander-
dc.date2019-07-29-
dc.date.accessioned2019-08-12T05:00:01Z-
dc.date.available2019-08-12T05:00:01Z-
dc.date.issued2019-12-
dc.identifier.citationLiver International 2019; 39(12): 2285-2290-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/21367-
dc.description.abstractDespite highly effective direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection, some patients experience virological relapse. Salvage regimens should include multiple agents to suppress emergence of resistance-associated substitutions (RAS) and minimise treatment failure. The combination of sofosbuvir (SOF) and elbasvir/grazoprevir (ELB/GZR) ±ribavirin (RBV) is an effective retreatment strategy for HCV genotype (GT)1 and 4 infection. We hypothesized that SOF and ELB/GZR (±RBV) would also be an effective salvage regimen for DAA-experienced GT3 patients. We evaluated the efficacy and safety of SOF/ELB/GZR±RBV in DAA-experienced participants with chronic HCV infection who had prior relapse. Participants were treated at four hospitals between December 2016 and March 2018 for either 12- or 16-weeks. The primary endpoint was sustained virological response at week 12 post-treatment (SVR12) using intention-to-treat analysis. There were 40 participants included in the analysis. The mean age was 53 years, 53% had GT3, 33% had GT1 infection, and 63% had cirrhosis. Fifty-eight percent were treated for 12 weeks, 42% were treated for 16 weeks, and 90% received RBV. The SVR12 rate was 98% overall, 100% in non-GT3 participants and 95% in GT3 participants. One GT3 cirrhotic participant relapsed. ELB/GZR was stopped at week 6 in one GT3 cirrhotic participant who switched to SOF/velpatasvir/RBV for a further 12 weeks and achieved SVR12. RBV dose reduction was required in two participants. Treatment was otherwise well tolerated. The combination of SOF/ELB/GZR±RBV is effective and safe for difficult-to-cure patients who relapse after first-line DAA, including those with cirrhosis and GT3 infection. This article is protected by copyright. All rights reserved.-
dc.language.isoeng-
dc.subjecthepatitis C-
dc.subjectresistance associated substitution-
dc.subjectretreatment-
dc.subjectsalvage-
dc.subjectvirological relapse-
dc.titleRetreatment with Elbasvir, Grazoprevir, Sofosbuvir +/- Ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.-
dc.typeJournal Article-
dc.identifier.journaltitleLiver International-
dc.identifier.affiliationMonash Health and Monash University, Melbourne, Australiaen
dc.identifier.affiliationWestern Health, Melbourne, Australiaen
dc.identifier.affiliationSt Vincent's Hospital and the University of Melbourne, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationVictorian Infectious Disease Reference Laboratory, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases, The Alfred and Monash University, Melbourne, Australiaen
dc.identifier.affiliationBurnet Institute, Melbourne, Australiaen
dc.identifier.doi10.1111/liv.14201-
dc.identifier.orcid0000-0003-0296-8624-
dc.identifier.pubmedid31355968-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Jun 24, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.